Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cost of COVID-19 vaccine nationalism could hit $1.2 trillion

By Brian Buntz | October 28, 2020

COVID-19 coronavirus

[Photo by Fusion Medical Animation on Unsplash]

Rand Europe, WHO and the president of Germany recently warned against vaccine nationalism.

The cost of nationalistic tendencies to hoard vaccines and prioritize vaccines for their citizenry could lead to a global reduction in gross domestic product of $1.2 trillion, according to the nonprofit think tank Rand Europe. By contrast, the global economic penalty of failing to develop a COVID-19 vaccine would be $3.4 trillion, according to the organization.

The think tank reasoned that the inability to control the virus internationally would extend its economic toll on various economic sectors.

WHO head Tedros Adhanom Ghebreyesus also warned on Oct. 25 that countries that focus vaccine efforts on their citizens could ultimately prolong the pandemic. The world should aim to “vaccinate some people in all countries rather than all people in some countries,” Ghebreyesus said in a virtual conference at the World Health Summit in Berlin.

German President Frank-Walter Steinmeier echoed that sentiment at the World Health Summit in Berlin. COVID-19 is “indifferent to the nationality of its victims. It will continue to overcome every barrier in the future if we do not confront it together,” he said.

Rand Europe concluded that even denying equal access to the vaccine to developing countries could have a global cost of $153 billion a year in GDP terms.

Meanwhile, providing vaccines to lower-income countries would cost an estimated $25 billion.

Rand Europe concluded that the return for every $1 high-income countries invest in distributing vaccines to low-income nations would be $4.8.

“Our findings suggest that there are real economic incentives for the higher income countries to drive vaccine development and distribution to ensure that the rest of the world has access to vaccines as soon as possible,” wrote Marco Hafner or Rand Europe, who was the study’s lead author.

 


Filed Under: Drug Discovery
Tagged With: covid-19, RAND Europe, vaccine, WHO
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE